Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published:September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like Australian scientists uncover new way to halt aggressive cancer growth July 28, 2025 Women speak more than men during early and middle adulthood February 5, 2025 Clever menu reshuffling leads diners to choose healthier and greener meals August 11, 2025